Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXRNASDAQ:LLITNASDAQ:LYRANASDAQ:MDAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$8.75-0.5%$7.88$6.55▼$10.00$42.32M-0.135,790 shs2,021 shsLLITLianluo Smart$10.42-2.7%$9.91$2.76▼$17.14$23.04M0.161.04 million shs514,371 shsLYRALyra Therapeutics$11.34-4.3%$7.63$3.81▼$37.50$15.03M-0.01185,380 shs217,174 shsMDAISpectral AI$1.97-7.5%$1.42$0.82▼$3.25$49.87M0.7853,800 shs453,892 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor+0.46%-1.01%+22.08%+7.46%-0.11%LLITLianluo Smart-13.98%+70.54%+125.00%+2,696.34%+1,086.18%LYRALyra Therapeutics-12.22%-53.22%+151.06%+37.79%-23.55%MDAISpectral AI+3.90%+19.66%+50.00%+37.42%+26.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXRDaxor3.9865 of 5 stars3.53.00.00.02.73.30.0LLITLianluo SmartN/AN/AN/AN/AN/AN/AN/AN/ALYRALyra Therapeutics3.0592 of 5 stars3.24.00.00.03.91.70.6MDAISpectral AI3.6358 of 5 stars3.75.00.00.03.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 3.00Buy$25.00185.71% UpsideLLITLianluo Smart 0.00N/AN/AN/ALYRALyra Therapeutics 2.33Hold$100.00781.83% UpsideMDAISpectral AI 3.33Buy$4.75141.12% UpsideCurrent Analyst Ratings BreakdownLatest LLIT, MDAI, DXR, and LYRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025MDAISpectral AIHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.503/18/2025MDAISpectral AIHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.503/17/2025DXRDaxorAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.75 ➝ $25.003/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$100.00 ➝ $100.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxor$2.13M19.86N/AN/AN/A∞LLITLianluo Smart$380K60.63N/AN/A($0.59) per share-17.66LYRALyra Therapeutics$1.19M12.68N/AN/A$1.56 per share7.27MDAISpectral AI$29.96M1.66N/AN/A($0.10) per share-19.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/ALLITLianluo Smart-$4.45MN/A0.00∞N/AN/AN/AN/AN/ALYRALyra Therapeutics-$62.68M-$60.50N/AN/AN/A-6,635.76%-125.07%-59.74%8/12/2025 (Estimated)MDAISpectral AI-$20.85M-$0.54N/AN/AN/A-40.78%N/A-77.87%N/ALatest LLIT, MDAI, DXR, and LYRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025LYRALyra Therapeutics-$7.50-$6.00+$1.50-$0.13$0.16 million$0.18 million3/27/2025Q4 2024MDAISpectral AI-$0.13-$0.06+$0.07-$0.41$6.83 million$7.60 million3/13/2025Q4 2024LYRALyra Therapeutics-$6.00-$8.00-$2.00-$0.16$0.21 million$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxor$0.030.34%N/AN/AN/ALLITLianluo SmartN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/AMDAISpectral AIN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/ALLITLianluo SmartN/A2.422.17LYRALyra TherapeuticsN/A3.643.64MDAISpectral AIN/A0.730.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%LLITLianluo Smart28.75%LYRALyra Therapeutics95.62%MDAISpectral AI67.08%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.00%LLITLianluo Smart22.90%LYRALyra Therapeutics3.25%MDAISpectral AI30.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor374.84 million1.98 millionNot OptionableLLITLianluo Smart62.21 millionN/ANot OptionableLYRALyra Therapeutics501.33 million62.39 millionOptionableMDAISpectral AI8325.32 million8.04 millionNot OptionableLLIT, MDAI, DXR, and LYRA HeadlinesRecent News About These CompaniesSpectral Ai Inc Share Chat (MDAI.US)June 12 at 12:22 AM | lse.co.ukDeepView® System highlighted at the annual British Burn Association conferenceJune 10 at 8:00 AM | globenewswire.comSpectral AI Announces Appointment of Stanley Micek as Chief Operating OfficerMay 30, 2025 | globenewswire.comSpectral AI Announces Voting Results from 2025 Annual Meeting of StockholdersMay 29, 2025 | globenewswire.comDeepView® System Achieves 95.3% Accuracy Evaluation as Published in Burns JournalMay 27, 2025 | finance.yahoo.comSpectral AI, Inc. (MDAI) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comSpectral AI Announces 2025 First Quarter Financial ResultsMay 13, 2025 | globenewswire.comWhat's Next: Spectral AI's Earnings PreviewMay 12, 2025 | benzinga.comBurn clinicians present positive findings of the DeepView® System’s accuracy at the American Burn Association annual meetingApril 30, 2025 | finance.yahoo.comBurn clinicians present positive findings of the DeepView® System's accuracy at the American Burn Association annual meetingApril 30, 2025 | globenewswire.comSpectral AI files to sell 2.84M shares of common stock for holdersApril 26, 2025 | markets.businessinsider.comGlobal AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic CollaborationsApril 16, 2025 | markets.businessinsider.comSpectral AI (MDAI) Secures $17.7 Million to Launch Burn Wound AI SystemApril 1, 2025 | msn.comSpectral AI Inc. (MDAI) Poised for FDA Approval with Revolutionary DeepView SystemMarch 30, 2025 | msn.comSpectral AI, Inc. (NASDAQ:MDAI) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.com10 AI Stocks Dominating the News This WeekMarch 28, 2025 | insidermonkey.comTop 8 AI News Updates Investors Should Not MissMarch 28, 2025 | insidermonkey.comSpectral AI reports Q4 EPS (41c) vs. (22c) last yearMarch 28, 2025 | markets.businessinsider.comSpectral AI, Inc. (MDAI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comSpectral AI Announces 2024 Fourth Quarter and Full Year Financial ResultsMarch 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLLIT, MDAI, DXR, and LYRA Company DescriptionsDaxor NASDAQ:DXR$8.75 -0.04 (-0.46%) As of 03:58 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Lianluo Smart NASDAQ:LLITLianluo Smart Limited, together with its subsidiaries, designs, develops, markets, and distributes medical products primarily in China and internationally. The company offers medical devices, including wearable sleep respiratory solutions, general hospital products, medical compressors, and related supporting products. It also provides technical services in relation to the detection and analysis of obstructive sleep apnea syndrome to hospitals and medical centers through medical wearable devices. In addition, the company distributes medical products, such as sleep apnea machines. Lianluo Smart Limited sells its products primarily through distributors; and directly to hospitals, physical examination centers, and sleep centers, as well as to individual consumers. The company was formerly known as Dehaier Medical Systems Limited and changed its name to Lianluo Smart Limited in November 2016. Lianluo Smart Limited was incorporated in 2003 and is headquartered in Beijing, China.Lyra Therapeutics NASDAQ:LYRA$11.34 -0.51 (-4.30%) Closing price 04:00 PM EasternExtended Trading$11.35 +0.01 (+0.05%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Spectral AI NASDAQ:MDAI$1.97 -0.16 (-7.51%) Closing price 04:00 PM EasternExtended Trading$2.03 +0.06 (+3.25%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
